دوره 14، شماره 2 - ( 4-1405 )
جلد 14 شماره 2 صفحات 0-0 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bashiri A, Bouzari Z, Netadj M, Yazdani S, Khafri S. Study of Factors Affecting the Failure of Methotrexate Treatment in Patients Diagnosed With Tubal Ectopic Pregnancy. Res Mol Med (RMM) 2026; 14 (2)
URL: http://rmm.mazums.ac.ir/article-1-639-fa.html
URL: http://rmm.mazums.ac.ir/article-1-639-fa.html
Study of Factors Affecting the Failure of Methotrexate Treatment in Patients Diagnosed With Tubal Ectopic Pregnancy. Research in Molecular Medicine. 1405; 14 (2)
چکیده: (218 مشاهده)
Background: Methotrexate (MTX) is the first-line treatment for stable tubal ectopic pregnancy(EP), but its failure can lead to serious complications. This study aimed to identify predictive factors for methotrexate treatment failure to improve patient selection.
Methods: In this retrospective cross-sectional study, 371 patients with EP treated with a single-dose methotrexate regimen (50 mg/m²) at Rouhani Hospital, Babol (2013-2024) were analyzed. Demographic, clinical (β-hCG, pain), sonographic (mass size, free fluid), and inflammatory indices (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) data were extracted from medical records. Treatment failure was defined as the need for surgery. Univariate and multivariate logistic regression were used to identify independent predictors, with ROC curves assessing their accuracy.
Results: The treatment failure rate was 9.7% (n=36). Multivariate analysis identified a larger mass size (OR=1.32; 95%CI:1.15-1.52; p<0.001) and a higher systemic immune-inflammation index (SII) (OR=1.03; 95%CI:1.00-1.06; p=0.036) as significant independent predictors of failure. Higher red blood cell count and platelet distribution width were protective factors. ROC analysis demonstrated high predictive accuracy for mass size (AUC=0.85) and SII (AUC=0.82) in distinguishing treatment outcomes.
Conclusion: Ectopic pregnancy mass size ≥23 mm and elevated SII are strong predictors of methotrexate treatment failure. These readily available parameters can serve as valuable tools for clinical decision-making, suggesting that primary surgery may be a preferable option for patients with these risk factors to avoid the complications of failed medical therapy.
Methods: In this retrospective cross-sectional study, 371 patients with EP treated with a single-dose methotrexate regimen (50 mg/m²) at Rouhani Hospital, Babol (2013-2024) were analyzed. Demographic, clinical (β-hCG, pain), sonographic (mass size, free fluid), and inflammatory indices (neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) data were extracted from medical records. Treatment failure was defined as the need for surgery. Univariate and multivariate logistic regression were used to identify independent predictors, with ROC curves assessing their accuracy.
Results: The treatment failure rate was 9.7% (n=36). Multivariate analysis identified a larger mass size (OR=1.32; 95%CI:1.15-1.52; p<0.001) and a higher systemic immune-inflammation index (SII) (OR=1.03; 95%CI:1.00-1.06; p=0.036) as significant independent predictors of failure. Higher red blood cell count and platelet distribution width were protective factors. ROC analysis demonstrated high predictive accuracy for mass size (AUC=0.85) and SII (AUC=0.82) in distinguishing treatment outcomes.
Conclusion: Ectopic pregnancy mass size ≥23 mm and elevated SII are strong predictors of methotrexate treatment failure. These readily available parameters can serve as valuable tools for clinical decision-making, suggesting that primary surgery may be a preferable option for patients with these risk factors to avoid the complications of failed medical therapy.
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
